Browse GRIK4

Summary
SymbolGRIK4
Nameglutamate receptor, ionotropic, kainate 4
Aliases GluK4; KA1; GRIK; EAA1; excitatory amino acid receptor 1; glutamate receptor KA1; Glutamate receptor KA-1; G ......
Chromosomal Location11q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane; Multi-pass membrane protein. Cell junction, synapse, postsynaptic cell membrane; Multi-pass membrane protein.
Domain PF01094 Receptor family ligand binding region
PF00060 Ligand-gated ion channel
PF10613 Ligated ion channel L-glutamate- and glycine-binding site
Function

Receptor for glutamate. L-glutamate acts as an excitatory neurotransmitter at many synapses in the central nervous system. The postsynaptic actions of Glu are mediated by a variety of receptors that are named according to their selective agonists.

> Gene Ontology
 
Biological Process GO:0007215 glutamate receptor signaling pathway
GO:0035235 ionotropic glutamate receptor signaling pathway
Molecular Function GO:0004970 ionotropic glutamate receptor activity
GO:0005216 ion channel activity
GO:0005230 extracellular ligand-gated ion channel activity
GO:0005231 excitatory extracellular ligand-gated ion channel activity
GO:0005234 extracellular-glutamate-gated ion channel activity
GO:0008066 glutamate receptor activity
GO:0015267 channel activity
GO:0015276 ligand-gated ion channel activity
GO:0015277 kainate selective glutamate receptor activity
GO:0022803 passive transmembrane transporter activity
GO:0022824 transmitter-gated ion channel activity
GO:0022834 ligand-gated channel activity
GO:0022835 transmitter-gated channel activity
GO:0022836 gated channel activity
GO:0022838 substrate-specific channel activity
GO:0030594 neurotransmitter receptor activity
Cellular Component GO:0008328 ionotropic glutamate receptor complex
GO:0032983 kainate selective glutamate receptor complex
GO:0034702 ion channel complex
GO:0042734 presynaptic membrane
GO:0043235 receptor complex
GO:0045211 postsynaptic membrane
GO:0097060 synaptic membrane
GO:0098793 presynapse
GO:0098794 postsynapse
GO:0098802 plasma membrane receptor complex
GO:0098878 neurotransmitter receptor complex
GO:1902495 transmembrane transporter complex
GO:1990351 transporter complex
> KEGG and Reactome Pathway
 
KEGG hsa04080 Neuroactive ligand-receptor interaction
hsa04724 Glutamatergic synapse
Reactome R-HSA-451308: Activation of Ca-permeable Kainate Receptor
R-HSA-451326: Activation of Kainate Receptors upon glutamate binding
R-HSA-451306: Ionotropic activity of Kainate Receptors
R-HSA-112316: Neuronal System
R-HSA-112314: Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell
R-HSA-112315: Transmission across Chemical Synapses
Summary
SymbolGRIK4
Nameglutamate receptor, ionotropic, kainate 4
Aliases GluK4; KA1; GRIK; EAA1; excitatory amino acid receptor 1; glutamate receptor KA1; Glutamate receptor KA-1; G ......
Chromosomal Location11q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between GRIK4 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolGRIK4
Nameglutamate receptor, ionotropic, kainate 4
Aliases GluK4; KA1; GRIK; EAA1; excitatory amino acid receptor 1; glutamate receptor KA1; Glutamate receptor KA-1; G ......
Chromosomal Location11q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of GRIK4 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolGRIK4
Nameglutamate receptor, ionotropic, kainate 4
Aliases GluK4; KA1; GRIK; EAA1; excitatory amino acid receptor 1; glutamate receptor KA1; Glutamate receptor KA-1; G ......
Chromosomal Location11q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of GRIK4 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.1870.392
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.4880.375
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0270.943
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.030.94
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.1190.918
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.2170.873
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.430.533
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.3410.775
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-1.1640.402
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.0010.999
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.4730.572
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.6740.00219
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of GRIK4 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141705.9-5.91
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.11.49.70.0589
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.11.79.40.0895
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.811.8-70.577
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.718.2-10.50.576
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91622.212.59.70.602
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 592022.2-2.21
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 382703.7-3.70.415
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolGRIK4
Nameglutamate receptor, ionotropic, kainate 4
Aliases GluK4; KA1; GRIK; EAA1; excitatory amino acid receptor 1; glutamate receptor KA1; Glutamate receptor KA-1; G ......
Chromosomal Location11q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of GRIK4. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolGRIK4
Nameglutamate receptor, ionotropic, kainate 4
Aliases GluK4; KA1; GRIK; EAA1; excitatory amino acid receptor 1; glutamate receptor KA1; Glutamate receptor KA-1; G ......
Chromosomal Location11q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of GRIK4. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by GRIK4.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolGRIK4
Nameglutamate receptor, ionotropic, kainate 4
Aliases GluK4; KA1; GRIK; EAA1; excitatory amino acid receptor 1; glutamate receptor KA1; Glutamate receptor KA-1; G ......
Chromosomal Location11q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of GRIK4. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolGRIK4
Nameglutamate receptor, ionotropic, kainate 4
Aliases GluK4; KA1; GRIK; EAA1; excitatory amino acid receptor 1; glutamate receptor KA1; Glutamate receptor KA-1; G ......
Chromosomal Location11q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of GRIK4 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolGRIK4
Nameglutamate receptor, ionotropic, kainate 4
Aliases GluK4; KA1; GRIK; EAA1; excitatory amino acid receptor 1; glutamate receptor KA1; Glutamate receptor KA-1; G ......
Chromosomal Location11q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between GRIK4 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolGRIK4
Nameglutamate receptor, ionotropic, kainate 4
Aliases GluK4; KA1; GRIK; EAA1; excitatory amino acid receptor 1; glutamate receptor KA1; Glutamate receptor KA-1; G ......
Chromosomal Location11q23.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting GRIK4 collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting GRIK4.
ID Name Drug Type Targets #Targets
DB00142Glutamic AcidSmall MoleculeAADAT, AASS, ABAT, ALDH18A1, ASNS, BCAT1, BCAT2, CCBL2, CPQ, DNPEP ......69